Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILITY OF DESCARTES-08 IN PATIENTS WITH DERMATOMYOSITIS AND ANTISYNTHETASE SYNDROME

Next Previous
Trial Profile

A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILITY OF DESCARTES-08 IN PATIENTS WITH DERMATOMYOSITIS AND ANTISYNTHETASE SYNDROME

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Descartes 08 (Primary)
  • Indications Antisynthetase syndrome; Dermatomyositis
  • Focus Registrational; Therapeutic Use
  • Sponsors Cartesian Therapeutics

Most Recent Events

  • 12 Jan 2026 According to a Cartesian Therapeutics media release, Cartesian announced the U.S. Food and Drug Administration (FDA) accepted the investigational new drug (IND) application for its planned Phase 2 trial in myositis.
  • 06 Dec 2025 New trial record
  • 14 Nov 2025 Following the pause in development of both Descartes-15 in multiple myeloma and Descartes-08 in SLE, the Company expects current cash resources to support planned operations, including initiation of its Phase 2 myositis trial, through mid-2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top